Shopping Cart

MagSense® Technology

A Medical Imaging Breakthrough

MagSense® technology is a new functional imaging agent that holds the promise of being more sensitive
and safer for detecting cancers and other critical diseases.

Play Video
Specialized bio-safe magnetic nanoparticles are coated with tumor-targeting molecules that are able to circulate through normal blood flow or local injection. When bound to a tumor the MagSense particles can then be detected by Magnetic Resonance Imaging scanners.

How is MagSense® technology better than other imaging methods?

MagSense® technology does not use ionizing radiation, radioactive tracers, or strong magnetic fields. And unlike existing imaging methods that can only identify a “region of interest” and can not differentiate benign tumors from malignant cancer, MagSense® nanoparticles are designed to be detectable a unique and differentiated image contrast when used with Magnetic Resonance Imaging.

MagSense® Advantages

More accurate

The bio-functionalized nanoparticles detect actual tumor cells not just an anatomically suspicious lesion.

Safer for Patients

The iron oxide nanoparticles are made of bio-safe materials, require no radiation and the core component iron is used up by the body. It has the potential to eliminate unnecessary biopsy procedures.

Accessible

The MagSense® imaging agent works with mainstream clinical MRI scanners as part of standard clinical diagnostic workflow.

MagSense Technology

MagSense® Nanoparticles

MagSense® nanoparticles are specially formulated as an injectable solution for each type of cancer. Combining the superparamagnetic properties of our proprietary PrecisionMRX® iron oxide nanoparticles with tumor targeting molecules, each MagSense® test is designed to maximize sensitivity for tumor detection while minimizing non-specific uptake or off-target signals.

Magnetite Nanoparticle Core

Uniformly sized superparamagnetic Fe3O4.

Protective Polymer Coating

Monolayer provides stability in aqueous suspensions.

Stealth Coating – PolyEthylene Glycol

Minimizes opsonization in biological applications.

Targeting Moieties

Antibodies, peptides or cancer specific small molecules provides specificity for targeting tumor cells.

How does MagSense® imaging technology work?

MagSense® nanoparticles result in unique and differentiable image contrast when imaged by MRI.

Bio-safe magnetic nanoparticles are attracted to the tumor and detected.

Play Video

Patients are given a low dose injection of the nanoparticle imaging agent.

Targeting molecules affixed to the nanoparticles, ensure high specificity for the cancer, and cause the nanoparticles to find and bind to tumor cells.

Only the tumor attached particles are detectable by magnetic sensors of Magnetic Relaxometry. With MRI, tumor bound MagSense particles result in unique image contrast, well   differentiated from nontumor containing tissue contrast.

The tiny nanoparticles are cleared by the body through the liver with the iron core being “repurposed” to produce ferratin used in hemoglobin production

How will it change cancer detection?

Most cancers are asymptomatic, growing unnoticed and undetected until the tumor has grown large enough to cause identifiable symptoms. Imaging methods like X-rays, ultrasound, and conventional MRI methods detect anatomical abnormalities and hence are only useful in detecting later-stage cancers when the tumor has grown to be tens- or hundreds of millions of cells. As a result, conventional cancer treatments start after cancer has grown large and has developed defensive mechanisms or has already progressed and spread.

Additionally, because current methods do not detect cancer cells and hence cannot distinguish benign tumors from true cancers, invasive biopsy procedures are needed to confirm if it is truly cancer, often resulting in needless patient anxiety.

A safer, non-invasive solution

MagSense® nanoparticles work within current standard cancer diagnosis and routine clinical assessment protocols.

MagSense® Applications

Breast Cancer

Breast cancer is the second leading cause of cancer related deaths in women and the second most common cancer diagnosed in women.

Prostate Cancer

Prostate cancer is the second most frequent form of cancer found in men with 1 in 7 men being diagnosed with prostate cancer during their lifetime.

Ovarian Cancer

Only about 20% of ovarian cancers are found at an early stage because ovarian cancer is largely asymptomatic.

Latest News

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

[HUBSPOT FORM EMBED CODE]